Pfizer Lowers Targeted Revenues for 2012; Wall Street Remains Skeptical
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's touts growth plans in emerging markets as the pharma prepares for the onset of Lipitor generics.
You may also be interested in...
A Management Shake-Up At Pfizer Raises Questions
2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.
A Management Shake-Up At Pfizer Raises Questions
2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.
Pfizer's Focus Is On "Bolt-On" Acquisitions After Wyeth Merger
Pfizer's business development strategy is on acquisitions up to "several billions" of dollars, management says.